Leading Product Revenue

November 14, 2025

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr.-Sep.	Annual (estimated)
Viltepso				17,530	21,782	10,349	21,100
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(2,386)	(4,800)
(U.S.)				(13,123)	(17,117)	(7,963)	(16,300)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	8,448	17,000
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	2,941	6,500
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	2,451	5,000
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,818	3,200
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Nov-2022	377	2,067	1,765	4,000
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	1,252	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,184	2,200
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,119	2,300
Erleada	apalutamide	prostate cancer	May-2019	-	-	-	6,300
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-
Profit in co-promotion				8,658	9,170	4,792	9,200
Revenues from the licensing of industrial property rights				40,304	45,585	24,181	47,000
Pharmaceuticals				125,105	138,654	68,561	145,000
Functional Food				23,150	21,577	11,086	23,000
Revenue				148,255	160,232	79,647	168,000

Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr.-Sep.	Annual (estimated)
Viltepso				17,530	21,782	10,349	21,100
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(2,386)	(4,800)
(U.S.)				(13,123)	(17,117)	(7,963)	(16,300)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	8,448	17,000
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	2,941	6,500
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	2,451	5,000
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,818	3,200
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Nov-2022	377	2,067	1,765	4,000
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	1,252	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,184	2,200
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,119	2,300
Erleada	apalutamide	prostate cancer	May-2019	-	-	-	6,300
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-
Profit in co-promotion				8,658	9,170	4,792	9,200
Profit in co-promotion				8,658	9,170	4,792	9,200
Revenues from the licensing of industrial property rights				40,304	45,585	24,181	47,000
Pharmaceuticals				125,105	138,654	68,561	145,000
Functional Food				23,150	21,577	11,086	23,000
Revenue				148,255	160,232	79,647	168,000

Back Number

ending March 2026(FY2025)	Q1PDF80 KB
ending March 2025(FY2024)	Q1PDF51 KB	Q1～2PDF46 KB	Q1～3PDF46 KB	Q1～4PDF33 KB
ending March 2024(FY2023)	Q1PDF48 KB	Q1～2PDF46 KB	Q1～3PDF42 KB	Q1～4PDF42 KB
ending March 2023(FY2022)	Q1PDF70 KB	Q1～2PDF61 KB	Q1～3PDF46 KB	Q1～4PDF58 KB
ending March 2022(FY2021)	Q1PDF44 KB	Q1～2PDF43 KB	Q1～3PDF48 KB	Q1～4PDF61 KB
ending March 2021(FY2020)	Q1PDF44 KB	Q1～2PDF51 KB	Q1～3PDF42 KB	Q1～4PDF43 KB
ending March 2020(FY2019)	Q1PDF43 KB	Q1～2PDF42 KB	Q1～3PDF43 KB	Q1～4PDF43 KB

Related Link

Business/Financial Information